12:00 AM
Jan 13, 2014
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Iroko sales and marketing update

Iroko launched Zorvolex submicron diclofenac in the U.S. to treat mild to moderate acute pain in adults. The wholesale acquisition cost of a...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >